

LV Noncompaction Cardiomyopathy or Just a Lot of Trabeculations?



Nay Aung, MD, Filip Zemrak, MD, Saidi A. Mohiddin, MBChB, MD, Steffen E. Petersen, MD, DPHIL, MPH


LEFT VENTRICULAR NONCOMPACTION (LVNC) IS CHARACTERIZED BY THE PRESENCE OF AN EXTENSIVE noncompacted myocardial layer lining the cavity of the left ventricle (LV) and potentially leads to cardiac failure, thromboembolism, and malignant arrhythmias (1). LVNC is a heterogeneous clinical condition, which often shows an overlap with other forms of established cardiomyopathy (2). Whether it is a distinct cardiomyopathy or a morphological variant of other types of nonischemic cardiomyopathy is still debated. There are uncertainties regarding its prevalence and incidence, natural history including prognosis, best diagnostic approaches, and management. Most published data on LVNC is likely to include a significant publication bias. Nonetheless, the reported morbidity and mortality of LVNC patients is high for both pediatric and adult subjects. LVNC may be familial in 30% to 50% of cases with autosomal dominant and X-linked recessive being the preponderant modes of inheritance. Even though the role of sarcomeric mutations in the pathogenesis of LVNC is recognized, the genotype-phenotype correlation is poor. Both echocardiogram and cardiac magnetic resonance (CMR) are widely utilized as imaging modalities to diagnose LVNC. In addition to superior spatial resolution and reproducibility, contrast-enhanced CMR can also assess late gadolinium enhancement pattern as a surrogate marker for myocardial fibrosis. Due to the risk of over-diagnosis of LVNC based on imaging criteria alone, interpretation of imaging findings in the clinical context is recommended.

We report 2 short cases of related individuals ([Figures 1 to 3](#), [Online Videos 1, 2, 3, and 4](#)) with increased LV trabeculations. The key learning points highlight the importance of LV systolic function and pre-test probability in formulating the management plan ([Figure 4](#)).


From the Barts Heart Centre, William Harvey Research Institute, NIHR Cardiovascular Biomedical Research Unit at Barts, Queen Mary University of London, London, United Kingdom. Dr. Petersen is a consultant to Circle Cardiovascular Imaging. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Manuscript received March 2, 2016; revised manuscript received March 21, 2016, accepted March 24, 2016.



FIGURE 1 CMR Images of Case 1 Demonstrating Prominent LV Trabeculations



Case 1: A 51-year-old Caucasian woman with no previous medical history presented with a 10-min episode of severe dizziness while sitting. She had no other cardiac symptoms. Cardiac magnetic resonance (CMR) showed a dilated left ventricle (LV) with severe global systolic impairment (left ventricular end-diastolic volume [LVEDV] 233 ml; left ventricular end-systolic volume [LVESV] 166 ml; left ventricular stroke volume [LVSV] 67 ml; left ventricular ejection fraction [LVEF] 29%) and features of LV noncompaction based on the diastolic noncompaction to compaction ratio in the long-axis steady-state free precession cines of 4:1 (**yellow arrow**) ([Online Videos 1 and 2](#)). A diagnosis of dilated cardiomyopathy with features of left ventricular noncompaction (LVNC) was made, and she was treated with conventional heart failure medical therapy. An interval CMR 2 years later demonstrated progressive LV disease (LVEDV 210 ml, LVESV 155 ml, LVSV 55 ml, LVEF 26%). She subsequently received a primary prevention implantable cardioverter-defibrillator.

FIGURE 2 Baseline CMR Images of Case 2

Case 2: A 32-year-old Caucasian man was referred to the cardiology clinic with palpitations and a family history of LVNC. He had no other cardiac symptoms. Baseline CMR showed a nondilated LV with good systolic function (LVEDV 180 mL, LVESV 75 mL, LVSV 105 mL, LVEF 58%) ([Online Video 3](#)). Hypertrabeculation of the LV myocardium was noted with a noncompaction to compaction (NC/C) ratio of 2.3:1, and there was no late gadolinium enhancement. In the absence of any cardiac symptoms or LV impairment, no therapy was introduced at this point. A second CMR 2 years later demonstrated an increase in LV internal dimensions and decline in LV systolic function (LVEDV 219 mL, LVESV 128 mL, LVSV 91 mL, LVEF 48%) ([Online Video 4](#)). The maximal NC/C ratio was 3.4:1. In view of these interval changes in CMR findings, a diagnosis of LVNC was made and a long-term follow-up was offered. Abbreviations as in [Figure 1](#).



ADDRESS FOR CORRESPONDENCE: Dr. Steffen E. Petersen, Barts Heart Centre, William Harvey Research Institute, NIHR Cardiovascular Biomedical Research Unit at Barts, Charterhouse Square, London, EC1M 6BQ, United Kingdom. E-mail: s.e.petersen@qmul.ac.uk.

REFERENCES

1. Arbustini E, Weidemann F, Hall JL. Left ventricular noncompaction: a distinct cardiomyopathy or a trait shared by different cardiac diseases? *J Am Coll Cardiol* 2014;64:1840-50.
2. Oechslin E, Jenni R. Left ventricular non-compaction revisited: a distinct phenotype with genetic heterogeneity? *Eur Heart J* 2011;32:1446-56.

APPENDIX For accompanying videos and their legends, please see the online version of this article.

KEY WORDS cardiac magnetic resonance, left ventricular noncompaction, left ventricular trabeculations